Clinical trial
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive…
NCT00085943 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00085943 |
|---|---|
| Title | KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks |
| Official title | See Detailed Description |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infection, Infection, Human Immunodeficiency Virus |
| Intervention type | Drug |
| Interventions | LEXIVA (GW433908), Ritonavir, KALETRA, EPIVIR, Ziagen, Abacavir/Lamivudine, Fosamprenavir |
| Enrollment | 866 |
| Start date | May 1, 2004 |
| First posted | Jun 21, 2004 |
| Last update posted | May 16, 2011 |
| Countries | Austria, Belgium, Canada, France, Germany, Italy, Latvia, Luxembourg, Poland, Portugal, Romania, Spain and 2 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: